Physiomics (AIM:PYC), an AIM-listed mathematical modelling, data science and biostatistics company supporting drug development, has secured multiple contract awards with a combined estimated value exceeding £200,000.
The package includes two extensions to existing clinical development engagements within its Biometrics service line: one with a clinical-stage biotechnology company focused on immunology and one with a company focused on infectious disease.
A third award, new rather than a renewal, is a Modelling and Simulation contract with a Boston-based biotechnology company developing novel immunotherapies for cancer.
Work across all three projects will span biostatistics, modelling and simulation, covering data analysis, development programme support and model-informed drug development.
"The mix of follow-on and new work across Biometrics and Modelling and Simulation demonstrates the increasing breadth of our offering and our ability to provide quantitative support to biotech clients across multiple stages of development," said Jesse Thissen, Chief Operating Officer.
The contracts represent the second and third follow-on engagements disclosed within the Biometrics service line, a division Physiomics has been scaling since its launch, building out processes and technical infrastructure for more complex client mandates.
